TrialSignal transduction and targeted therapy2026

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.

Fan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.